31 / 7 / 2025 THU

Arab Company for Pharmaceuticals and Chemical Industries (ADCI)

✓ Financial period ending June 30, 2025

Revenues: EGP 1.1 billion

Net profit: EGP 223 million

Earnings per share: EGP 16.24

P/E ratio: 7.9x

✓ Financial period ending June 30, 2024

Revenues: EGP 785 million

Net profit: EGP 102 million

Earnings per share: EGP 14.72

29 / 7 / 2025 TUE

Memphis Pharmaceuticals and Chemical Industries (MPCI)

Announces its unaudited financial results
✓ Fiscal year ending June 30, 2025

Revenues: EGP 1.5 billion

Net profit: EGP 504.9 million

Earnings per share: EGP 23.7

P/E ratio: 3.8x

✓ Fiscal year ending June 30, 2024

Revenues: EGP 871.9 million

Net profit: EGP 191.4 million

Earnings per share: EGP 14.5

7 / 7 / 2025 Mon

Rameda RMDA

The dividend distribution of EGP 0.106 per share will be distributed in two installments.

✓ The first installment, EGP 0.053, will be paid starting July 10, 2025.

✓ The second installment, EGP 0.053, will be paid starting November 27, 2025.

✓ The right to the dividend will be transferred to the buyer until the end of the session on July 7, 2025.

30 / 6 / 2025 Mon

Memphis Pharmaceuticals (MPCI)

The semi-annual disclosure form for the use of capital increase proceeds states:

** 60% of the capital increase proceeds were used to repay shareholders’ creditors (the Holding Company for Pharmaceuticals).*

40% of the capital increase proceeds were used to improve the company’s productivity, meet its raw material needs, and address increasing operating costs.

The total amount raised is EGP 171 million.

28 / 5 / 2025 WED

Rameda RMDA

The dividend distribution for the fiscal year ending 2024 was approved. The dividends will be distributed as follows:

✓ EGP 18 million in cash dividends to employees

✓ EGP 160 million in cash dividends to shareholders, at 10,589 piasters per share

✓ EGP 122.25 million in bonus shares to shareholders, at 0.3236 bonus shares per share

Ibn Sina Pharma ISPH

The company has agreed to replace Ibn Sina Pharma with a new investor in the financial lease contract related to the land, building, and equipment of Al Shorouk Hospital, for EGP 670 million. This is part of the management’s plan to sell non-strategic assets and reduce financial leasing costs.

Expected Results

☑ Debt reduction of approximately EGP 500 million by removing the lease contract from Ibn Sina Pharma’s balance sheet.

☑ Annual expense savings of approximately EGP 150 million (interest and depreciation), the impact of which will be reflected in the income statement starting June 2025.

☑ Achievement of a capital gain of approximately EGP 27 million after deducting liabilities and investments associated with the asset.

21 / 5 / 2025 WED

Prices of 25% of Imported Medicines in Egypt Are Expected to Decrease

Head of the Pharmaceutical Division: The executive order announced by Trump, which reduces medicine prices in the US by 30 to 80%, will contribute to reducing the import bill for 25% of the medicines Egypt imports annually over the coming period. This means that reducing medicine prices in the US will result in a similar reduction for the same items imported to Egypt, in compliance with the price of the country of origin, as a quarter of the medicines Egypt imports annually come from the United States.
Egypt’s import bill from the medical industry amounted to $4.7 billion last year, including medicine imports worth approximately $1.79 billion. Trump’s executive order will reduce Egypt’s medicine import bill from the United States by approximately half a billion dollars annually. (Al Arabiya News)